ArticleThe open cardiovascular medicine journal2011
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.
Article in The open cardiovascular medicine journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 77 citations in OpenAlex.
- Metabolic Syndrome in Adolescents: Definitions, Criteria, and Health Implications.Advances in experimental medicine and biology · 2026Review
- Association between Atherogenic Dyslipidemia and Subclinical Myocardial Injury in the General Population.Journal of clinical medicine · 2024Article
- Evaluation of levels of uric acid and lipid profile in hospitalized patients with diabetes.BMC research notes · 2023Article
- Insight into the Evolving Role of PCSK9.Metabolites · 2022Review
- Article
- Dehydrozingerone inhibits renal lipotoxicity in high-fat diet-induced obese mice.Journal of cellular and molecular medicine · 2021Article
- Comparative study on fasting and postprandial lipid profile in type 2 diabetes mellitus.Journal of family medicine and primary care · 2021Article
- Pathophysiology of Type 2 Diabetes Mellitus.International journal of molecular sciences · 2020Review
- New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease.European cardiology · 2020Review
- The polyphenol-rich extract from chokeberry (Nutrition & metabolism · 2020Article
- Article
- Impediments to clinical application of exercise interventions in the treatment of cardiometabolic disease.Canadian family physician Medecin de famille canadien · 2019Review
- Therapeutic approaches to drug targets in atherosclerosis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Review
- Cubilin maintains blood levels of HDL and albumin.Journal of the American Society of Nephrology : JASN · 2014Article
- Relations of serum soluble E-selectin and adiponectin with enlarged perivascular spaces in patients with recent lacunar infarction.CNS neuroscience & therapeutics · 2014Article
- A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect.BioMed research international · 2014Review
- Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study.Archives of medical science : AMS · 2013Article
- A comparative study on the fasting and the postprandial dyslipidaemia in type 2 diabetes mellitus.Journal of clinical and diagnostic research : JCDR · 2013Article
- Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.Nutrients · 2013Review
- New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.Evidence-based complementary and alternative medicine : eCAM · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). The predominant features of dyslipidaemia in these disorders include increased flux of free fatty acids (FFA), raised triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) levels, a predominance of small, dense (atherogenic) low density lipoprotein cholesterol (LDL) particles and raised apolipoprotein (apo) B values Posprandial hyperlipidaemia may also be present. Insulin resistance (IR) appears to play an important role in the pathogenesis of dyslipidaemia in obesity, MetS and T2DM. The cornerstone of treatment of this IR-related dyslipidaemia is lifestyle changes and in diabetic patients, tight glycaemic control. In addition to these measures, recent clinical trials showed benefit with statin treatment. Nevertheless, a substantial percentage of patients treated with statins still experience vascular events. This residual vascular risk needs to be addressed. This review summarizes the effects of hypolipidaemic drug combinations (including statins with cholesterol ester protein inhibitors, niacin, fibrates or fish oil, as well as fibrate-ezetimibe combination) on the residual vascular risk in patients with obesity, MetS or T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.